Stocks · Healthcare · Medical - Diagnostics & Research
OPKO Health, Inc. OPK
$1.56 -0.64% Close, Oct 2, 2026 · NASDAQ · Market cap $1.16B
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is in an uptrend: above its 200-day average for 48 trading days, with the 50-day average above the 200-day.
- Revenue over the last four quarters was $587.9M, down 11.5% from a year earlier, accelerating from -15.7% a quarter earlier.
- The diluted share count fell 4.2% in a year, mainly through buybacks.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth24Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 19%
- Revenue growth, 3-year CAGRBottom 9%
- Revenue growth accelerationTop 19%
Quality24Very weak
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 42%
- Gross marginBottom 20%
- Operating marginBottom 41%
- Accruals (lower is better)Bottom 12%
- Net debt / EBITDA (lower is better)Bottom 40%
- Interest coverBottom 44%
Value63Neutral
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 46%
- Free-cash-flow yieldBottom 34%
- EBITDA / enterprise valueTop 29%
- Sales / enterprise valueTop 26%
Momentum67Positive
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 41%
- 6-month returnTop 27%
- 1-year return vs S&P 500Bottom 44%
- Distance from 52-week highTop 17%
- Trend checklist (0–4)Top 20%
Revisions69Positive
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 8%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 27%
- Upside to consensus price targetTop 42%
Stability58Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 15%
- Maximum drawdown, 3 yearsTop 20%
- Beta vs S&P 500 (lower is better)Top 20%
- Net debt / EBITDA (lower is better)Bottom 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -15.7% | -11.5% | ↑ |
| Gross margin | 26.7% | 31.0% | ↑ |
| Operating margin | -22.0% | -25.5% | ↓ |
| FCF margin | -39.0% | -22.8% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -11.5% | -15.7% | ↑ | Bottom 19% |
| Gross margin | 31.0% | 26.7% | ↑ | Bottom 20% |
| Operating margin | -25.5% | -22.0% | ↓ | Bottom 41% |
| Net margin | -12.4% | -26.7% | ↑ | — |
| Free-cash-flow margin | -22.8% | -39.0% | ↑ | — |
| Return on invested capital | -9.1% | — | Top 42% | |
| Revenue growth, 3-year CAGR | -15.5% | — | Bottom 9% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 2.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -3.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 1.97×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -3.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 4.04%
- Shareholder yield
- 4.04%
- Share count change, 1 year
- -4.2%
- Share count change, 3-year CAGR
- +0.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 27, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +95.1%
- Average 2-day reaction, last 8
- -0.7%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $2.87
- Target vs current price
- +84.0%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 62%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 27, 2026 | +87.5% | +1.6% | +8.2% | +21.3% | — |
| Apr 28, 2026 | +0.0% | +0.8% | -7.5% | +7.5% | -2.5% |
| Feb 26, 2026 | +42.9% | +1.7% | +1.7% | +0.8% | +8.5% |
| Oct 29, 2025 | +250.0% | -0.7% | -3.5% | -6.2% | -9.7% |
| Jul 31, 2025 | -58.3% | -4.5% | -5.2% | +6.0% | +13.4% |
| Apr 30, 2025 | -66.7% | -1.4% | -8.6% | -7.1% | -2.1% |
| Feb 27, 2025 | +112.5% | -1.8% | +16.9% | +6.6% | -23.5% |
| Nov 7, 2024 | +130.0% | -1.4% | +8.8% | +6.8% | +9.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 27, 2026 | -$0.01 | -$0.08 | +87.5% | $163.5M |
| Apr 28, 2026 | -$0.07 | -$0.07 | +0.0% | $124.2M |
| Feb 26, 2026 | -$0.04 | -$0.07 | +42.9% | $148.5M |
| Oct 29, 2025 | $0.03 | -$0.02 | +250.0% | $151.7M |
| Jul 31, 2025 | -$0.19 | -$0.12 | -58.3% | $156.8M |
| Apr 30, 2025 | -$0.10 | -$0.06 | -66.7% | $150.0M |
| Feb 27, 2025 | $0.01 | -$0.08 | +112.5% | $183.6M |
| Nov 7, 2024 | $0.03 | -$0.10 | +130.0% | $173.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 27.0× | — | — | Top 29% |
| EV / Sales | 2.14× | — | — | Top 26% |
| Free-cash-flow yield | -11.51% | — | — | Bottom 34% |
| Earnings yield | -6.12% | — | — | Top 46% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 32
- Days above the 200-day average
- 48
- 50-day average slope (20 days)
- +7.5%
- 200-day average slope (20 days)
- +2.1%
- Distance from 50-day average
- +4.2%
- Distance from 200-day average
- +18.0%
- RSI (14)
- 47.5
- Relative volume
- 0.53×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 83.8%
- Volatility vs own 5-year history
- 93th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.58
- Correlation with S&P 500
- 0.23
- Current drawdown from 1-year high
- -9.8%
- Maximum drawdown, 3 years
- -46.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 1, 2021 | Mar 18, 2024 | -85.5% | 786 days | Not yet recovered |
| Oct 9, 2020 | Nov 9, 2020 | -29.3% | 21 days | 14 days (Nov 30, 2020) |
| Dec 2, 2020 | Dec 28, 2020 | -19.5% | 17 days | 18 days (Jan 25, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.16B
- EPS, diluted (TTM)
- -$0.10
- Revenue (TTM)
- $587.9M
- 52-week range
- $0.98 – $1.75
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.77B | $1.00B | $863.5M | $713.1M | $606.9M |
| Gross profit | $581.5M | $288.2M | $318.1M | $311.0M | $128.1M |
| Operating income | $18.8M | -$226.3M | -$157.0M | -$152.1M | -$219.0M |
| Net income | -$30.1M | -$328.4M | -$188.9M | -$53.2M | -$225.7M |
| EPS (diluted) | -$0.05 | -$0.46 | -$0.25 | -$0.08 | -$0.30 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $173.6M | $183.6M | $150.0M | $156.8M | $151.7M | $148.4M | $124.2M | $163.6M |
| Net income | $24.9M | $14.0M | -$67.6M | -$148.4M | $21.6M | -$31.3M | -$54.8M | -$8.4M |
| EPS (diluted) | $0.03 | $0.02 | -$0.10 | -$0.19 | $0.03 | -$0.04 | -$0.07 | -$0.01 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $38.3M | -$95.2M | -$28.2M | -$183.5M | -$178.5M |
| Capital expenditure | -$32.2M | -$24.6M | -$16.3M | -$25.0M | -$12.3M |
| Free cash flow | $6.2M | -$119.8M | -$44.5M | -$208.5M | -$190.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $1.1M | -$774,000 | -$272,000 | -$90.2M | -$47.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $300.8M
- Total assets
- $1.83B
- Total liabilities
- $645.3M
- Total debt
- $392.3M
- Net debt
- $91.5M
- Shareholders’ equity
- $1.18B
As of Jun 30, 2026 (filed Jul 27, 2026).
Short interest
- Shares sold short
- 35,987,629
- Days to cover
- 10.55
- Change vs previous report
- +4.1%
FINRA short interest, settlement date Sep 15, 2026.